Advertisement
Screener

AIM IMMUNOTECH INC. (AIM) Graph

AIM Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $26.00K; Cost of revenue (m); Research and development $589.00K; Net income -$3.79M.
  • 2026-03-31: Revenue $22.00K; Cost of revenue (m); Research and development $482.00K; Net income -$3.02M.
  • 2025-12-31: Revenue $21.00K*; Cost of revenue (m); Research and development $1.06M*; Net income -$4.17M*.
  • 2025-09-30: Revenue $26.00K; Cost of revenue (m); Research and development $607.00K; Net income -$3.28M.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

AIM revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Revenue$26.00KOperating income-$3.51MOther income, net$21.00KResearch & development$589.00KNet income-$3.79M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentNet income
2026-06-30$26.00K(m)$589.00K-$3.79M
2026-03-31$22.00K(m)$482.00K-$3.02M
2025-12-31$21.00K*(m)$1.06M*-$4.17M*
2025-09-30$26.00K(m)$607.00K-$3.28M
2025-06-30$25.00K(m)$1.17M-$2.79M
2025-03-31$16.00K(m)$1.08M-$3.71M
2024-09-30$35.00K(m)$1.44M-$3.70M
2024-06-30$50.00K(m)$1.15M-$1.84M
2024-03-31$40.00K(m)$1.95M-$5.82M
2023-09-30$46.00K(m)$2.73M-$7.82M
2023-06-30$42.00K(m)$2.95M-$4.91M
2023-03-31$49.00K(m)$2.05M-$3.66M
2022-09-30$21.00K(m)$1.37M-$6.38M
2022-06-30$30.00K(m)$2.48M-$4.85M
2022-03-31$33.00K(m)$1.04M-$3.82M
2021-09-30$33.00K(m)$2.01M-$3.83M
2021-06-30$23.00K(m)$1.32M-$5.88M
2021-03-31$28.00K(m)$1.42M-$3.58M
2020-09-30$36.00K(m)$1.10M-$3.31M
2020-06-30$40.00K(m)$1.46M-$3.37M
2020-03-31$45.00K(m)$898.00K-$3.81M
2019-09-30$61.00K(m)$1.19M-$2.95M
2019-06-30$29.00K(m)$1.10M-$2.04M
2019-03-31(m)(m)$928.00K-$3.37M
2018-09-30$38.00K(m)$1.59M-$3.08M
2018-06-30$33.00K(m)$1.34M-$2.42M
2018-03-31$56.00K(m)$855.00K-$2.71M
2017-09-30$90.00K(m)$787.00K-$1.25M
2017-06-30$213.00K(m)$1.11M-$2.19M
2017-03-31$84.00K(m)$1.39M-$2.82M
2016-09-30$22.00K(m)$1.34M-$2.86M
2016-06-30$15.00K(m)$900.00K-$1.30M
2016-03-31$39.00K(m)$1.00M-$2.16M
2015-09-30$23.00K$353.00K$1.97M-$3.80M
2015-06-30$47.00K$507.00K$2.44M-$4.84M
2015-03-31$36.00K$372.00K$2.67M-$3.44M
2014-09-30$45.00K$306.00K$1.89M(m)
2014-06-30$36.00K$294.00K$2.33M(m)
2014-03-31$76.00K$323.00K$2.33M(m)
2013-12-31$36.00K(m)(m)(m)
2013-09-30$36.00K$252.00K$2.17M(m)
2013-06-30$36.00K$635.00K$2.32M(m)
2013-03-31$42.00K$191.00K$2.34M(m)
2012-12-31$53.00K(m)(m)(m)
2012-09-30$39.00K$988.00K$2.36M(m)
2012-06-30$49.00K$208.00K$1.74M(m)
2012-03-31$72.00K$280.00K$1.67M(m)
2011-12-31$38.00K(m)(m)(m)
2011-09-30$45.00K$217.00K$1.75M(m)
2011-06-30$36.00K$204.00K$1.62M(m)
2011-03-31$42.00K$193.00K$1.64M(m)
2010-12-31$27.00K(m)(m)(m)
2010-09-30$35.00K$181.00K$1.81M(m)
2010-06-30$41.00K$328.00K$1.69M(m)
2010-03-31$32.00K(m)(m)(m)

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentNet income
2026-06-30$48.00K(m)$1.07M-$6.81M
2025-06-30$41.00K(m)$2.25M-$6.50M
2024-06-30$90.00K(m)$3.10M-$7.65M
2023-06-30$91.00K(m)$5.00M-$8.57M
2022-06-30$64.00K(m)$3.51M-$8.67M
2021-06-30$52.00K(m)$2.74M-$9.46M
2020-06-30$85.00K(m)$2.34M-$7.16M
2019-06-30$29.00K(m)$2.02M-$5.39M
2018-06-30$89.00K(m)$2.20M-$5.13M
2017-06-30$297.00K(m)$2.50M-$5.01M
2016-06-30$54.00K(m)$1.90M-$3.47M
2015-06-30$83.00K$879.00K$5.11M-$8.29M
2014-06-30$112.00K$617.00K$4.66M(m)
2013-06-30$78.00K$826.00K$4.65M(m)
2012-06-30$121.00K$488.00K$3.40M(m)
2011-06-30$78.00K$397.00K$3.26M(m)
2010-06-30$73.00K$468.00K$3.69M(m)

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentNet income
2025-09-30$67.00K(m)$2.86M-$9.78M
2024-09-30$125.00K(m)$4.53M-$11.35M
2023-09-30$137.00K(m)$7.74M-$16.39M
2022-09-30$85.00K(m)$4.88M-$15.06M
2021-09-30$85.00K(m)$4.75M-$13.28M
2020-09-30$121.00K(m)$3.44M-$10.47M
2019-09-30$90.00K(m)$3.21M-$8.34M
2018-09-30$127.00K(m)$3.79M-$8.21M
2017-09-30$387.00K(m)$3.28M-$6.27M
2016-09-30$76.00K(m)$3.24M-$6.33M
2015-09-30$106.00K$1.23M$7.08M-$12.09M
2014-09-30$157.00K$923.00K$6.55M(m)
2013-09-30$114.00K$1.08M$6.83M(m)
2012-09-30$160.00K$1.48M$5.76M(m)
2011-09-30$123.00K$614.00K$5.01M(m)
2010-09-30$108.00K$649.00K$5.50M(m)

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentNet income
2025-12-31$88.00K(m)$3.92M-$13.96M
2024-12-31$170.00K(m)$6.20M-$17.32M
2023-12-31$202.00K(m)$10.94M-$28.96M
2022-12-31$141.00K(m)$6.99M-$19.45M
2021-12-31$135.00K(m)$7.67M-$19.13M
2020-12-31$163.00K(m)$5.72M-$14.40M
2019-12-31$140.00K(m)$4.65M-$9.40M
2018-12-31$367.00K(m)$4.78M-$9.83M
2017-12-31$437.00K(m)$4.10M-$8.26M
2016-12-31$92.00K(m)$5.11M-$7.50M
2015-12-31$133.00K(m)$8.04M-$15.23M
2014-12-31$197.00K$1.25M$8.99M-$17.45M
2013-12-31$150.00K$1.23M$8.36M-$16.23M
2012-12-31$213.00K$1.99M$9.51M(m)
2011-12-31$161.00K$1.04M$6.72M(m)
2010-12-31$135.00K$1.34M$7.61M(m)
2009-12-31$111.00K$584.00K$7.00M(m)

Similar stocks

Stock NameCountryMarket CapPE Ratio
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B
CERO THERAPEUTICS HOLDINGS, INC. (CERO)United States$0.007B
PharmaCyte Biotech, Inc. (PMCB)United States$0.005B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
WINDTREE THERAPEUTICS INC /DE/ (WINT)United States$0.003B-0.32
VivoSim Labs, INC. (VIVS)United States$0.003B
Calidi Biotherapeutics, Inc. (CLDI)United States$0.003B
CURIS INC (CRIS)United States$0.002B-0.05
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
Silexion Therapeutics Corp (SLXN)$0.001B